EU approves sale of new Alzheimer's drug, with conditions

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for early-stage Alzheimer's disease, to be sold in the EU under strict conditions. Lecanemab has been hailed by Alzheimer's researchers and charities for being the first approved treatment that tackles the early stages of the disease, rather than managing the symptoms.